Simulations Plus acquisition by Altaris closes at $18.50 per share

Bitget2026/10/06 13:15

Altaris completed its acquisition of Simulations Plus, paying $18.50 per share in cash. Simulations Plus became privately held, ending trading of its common stock on the Nasdaq Global Select Market. The deal was first disclosed on June 16, 2026. Closing pairs Simulations Plus with Altaris-owned Chemical Computing Group to build a broader drug discovery and development software platform. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610060915BIZWIRE_USPR_____20261006_BW258966) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Citi: French fiscal risks may cause ECB to pause rate hikes after December, euro likely to drop below 1.10

华尔街见闻•2026/10/10 07:43

Morgan Stanley raises CME Group price target to $337

格隆汇•2026/10/10 07:37

Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Chaincatcher•2026/10/10 07:19

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21